Identifying predictors of treatment response and molecular changes induced by neoadjuvant chemotherapy and endocrine therapy in hormone receptor-positive/HER2-negative breast cancer: the NEOENDO translational study

ESMO Open, Год журнала: 2024, Номер 9(12), С. 103989 - 103989

Опубликована: Ноя. 27, 2024

Язык: Английский

---

Efficacy and safety of antibody-drug conjugates in pretreated HER2-low metastatic breast cancer: A systematic review and network meta-analysis

Cancer Treatment Reviews, Год журнала: 2024, Номер 132, С. 102865 - 102865

Опубликована: Дек. 19, 2024

Язык: Английский

---

A population‑based propensity score matching analysis of neoadjuvant compared to adjuvant chemotherapy in luminal breast cancer

Scientific Reports, Год журнала: 2025, Номер 15(1)

Опубликована: Март 20, 2025

This study evaluated the long-term prognosis of patients with luminal (HR+/HER2−) breast cancer who underwent either neoadjuvant or adjuvant chemotherapy. Between January 2014 and December 2018, 1065 h+/HER2− were retrospectively analyzed. Each patient receiving chemotherapy was matched two using a 1:2 propensity score matching (PSM) approach. After matching, 47 89 included. The clinical pathological characteristics both groups compared, risk factors for postoperative events assessed alongside survival analysis. Following well balanced. identified lower progesterone receptor (PR) expression, histological grade III, lymph node metastasis as independent recurrence-free (RFS). No significant difference in RFS observed between It is recommended that HR+/HER2− exhibit poor response to should undergo early surgery, personalized treatment decisions based on findings.

Язык: Английский

---

Comprehensive analysis of HER2 Low Breast Cancer Response to Neoadjuvant Chemotherapy, a Retrospective Cohort Study

Clinical Breast Cancer, Год журнала: 2025, Номер unknown

Опубликована: Март 1, 2025

Язык: Английский

---

Gene Expression Signatures for Guiding Initial Therapy in ER+/HER2- Early Breast Cancer

Cancers, Год журнала: 2025, Номер 17(9), С. 1482 - 1482

Опубликована: Апрель 28, 2025

In triple-negative (TNBC) and human epidermal growth factor receptor 2-positive (HER2+) breast cancer patients, neoadjuvant systemic therapy is the standard recommendation for tumors larger than 2 cm. Monitoring response to primary allows assessment of treatment effects, need breast-conserving surgery (BCS), achievement pathological complete responses (pCRs). estrogen receptor-positive/HER2-negative (ER+/HER2-) cancer, benefit strategies controversial, as they have shown lower tumor downstaging pCR rates compared other cancers. recent decades, several gene expression assays been developed tailor adjuvant treatments in ER+/HER2- early (EBC) identify patients that will most from chemotherapy (CT) those at low risk who could be spared undergoing CT. It still a challenge (CT or endocrine (ET)). Here, we review published data on common signatures (MammaPrint (MP), BluePrint (BP), Oncotype Dx, PAM50, Breast Cancer Index (BCI), EndoPredict (EP)) their ability predict treatment, well possibility using them core needle biopsies. Additionally, changes after ongoing clinical trials related utility setting.

Язык: Английский

---

Intratumor heterogeneity in breast cancer: Tracing its origins and translating findings into clinical practice

Precision medicine and engineering., Год журнала: 2024, Номер 1(1), С. 100006 - 100006

Опубликована: Авг. 28, 2024

Язык: Английский

---

The intersection of the HER2-low subtype with endocrine resistance: the role of interconnected signaling pathways

Frontiers in Oncology, Год журнала: 2024, Номер 14

Опубликована: Ноя. 22, 2024

Since its introduction in the 1970s, endocrine therapy that targets estrogen receptor alpha (ERα) signaling pathway has had tremendous success clinic positive (ER+) breast cancer. However, resistance to eventually develops virtually all patients with metastatic disease. Endocrine is a primary unaddressed medical need for ER+ cancer patients. It been shown tumors become resistant through various mechanisms, converging on acquisition of genetic alterations ER, components MAP kinase pathway, or transcription factors (TFs). For instance, mutations human epidermal growth factor receptor-2 (HER2) lead complete current therapies including aromatase inhibitors, selective modulators, and degraders, as well cross-resistance CDK4/6 inhibitors (CDK4/6is). Emerging evidence points an intriguing connection between endocrine-resistant HER2-low subtype. Specifically, recent studies our analysis publicly available dataset both indicate conferred acquired can often be classified rather than HER2-0/HER2-negative. Limited data suggest also accompanied by subtype switch. Therefore, we there underappreciated association resistance. In this perspective piece, explore linking pathways are networks intersect effectively targeted.

Язык: Английский

---

Integrated Nomogram to Predict HER2 Expression in Breast tumor: Clinical, Ultrasound, and Photoacoustic Imaging Approaches

European Journal of Cancer, Год журнала: 2024, Номер 209, С. 114259 - 114259

Опубликована: Авг. 3, 2024

Язык: Английский

---

“Influence of histopathological changes after neoadjuvant chemotherapy on the survival of breast cancer patients”

Cancer Treatment and Research Communications, Год журнала: 2024, Номер 43, С. 100886 - 100886

Опубликована: Янв. 1, 2024

Язык: Английский

---